Company Overview - IBA (Ion Beam Applications S.A.) is a global leader in particle accelerator technology, specializing in proton therapy, industrial sterilization, radiopharmaceuticals, and dosimetry [5][6] - The company is headquartered in Louvain-la-Neuve, Belgium, and employs approximately 2,100 people worldwide [5] - IBA is recognized as a certified B Corporation (B Corp), meeting high standards of verified social and environmental performance [5] Shareholder Information - The total capital of IBA is EUR 42,502,318.54, with 30,282,218 securities conferring voting rights [2] - The existing voting rights amount to 40,516,629, which is the denominator for calculating the quota of voting rights that can trigger notification requirements [2] - The statutory ceiling for voting at general meetings is set at 35% of the total voting rights, equating to 14,180,820.2 votes [5] Voting Rights and Regulations - IBA has introduced loyalty voting rights, which apply to registered shares held for at least two consecutive years [3] - The calculation method for loyalty voting rights is based on the LIFO (last in, first out) principle [4] - The company must publish changes in the number of voting rights at the end of each calendar month when such changes occur [1][2]

Company Leadership Changes - PharmaLogic Holdings Corp. appointed Etienne Montagut as President and Chief Executive Officer effective June 1, 2025 [1] - Steve Chilinski, who led the company for 13 years, retired as CEO and will take on the role of Executive Chairman of the Board [3] Leadership Experience - Etienne Montagut has over 25 years of senior leadership experience in the pharmaceutical sector, with a proven track record in driving growth and executing strategic transformations globally [2] Company Overview - PharmaLogic is a leading global contract development and manufacturing organization (CDMO) specializing in diagnostic and therapeutic radiopharmaceuticals [4] - The company operates more than 45 facilities across the U.S., Puerto Rico, Canada, and Norway, providing comprehensive solutions for the development, manufacturing, and distribution of radiopharmaceutical products [4] Business Segments - The diagnostics business is rapidly expanding, utilizing advanced technologies to improve patient access to novel diagnostics in oncology, cardiology, and Alzheimer's disease [5] - PharmaLogic is the only cGMP-compliant CDMO manufacturing and distributing a commercial radiopharmaceutical therapeutic in over 30 countries [5] Strategic Focus - The company is dedicated to enhancing global patient access to radiopharmaceuticals through strategic development partnerships with industry innovators [6]

Immediate Release – May 30th, 2025 Louvain-la-Neuve, Belgium, May 30th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity unti ...

Company Overview - Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies [5] - The company is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan [5] - Telix aims to address significant unmet medical needs in oncology and rare diseases through its portfolio of clinical and commercial stage products [5] Investor Day Announcement - Telix will host an Investor Day on June 11, 2025, in New York City, focusing on growth opportunities in its commercial and clinical portfolio [1][2] - The event will feature presentations from key members of the Telix leadership team, including the Managing Director and Group CEO, Dr. Christian Behrenbruch, and other executives [3] - Key Opinion Leaders will also share insights on the clinical utility and opportunities for Telix's theranostic candidates during the event [3] Attendance Information - Attendance at the Investor Day is by invitation only for qualified institutional investors and analysts, and advance registration is required [4][5]